Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Acquired immunotherapy resistance in PDA (RNA-seq)

ABSTRACT: Acquired immunotherapy resistance in PDA (RNA-seq)

PROVIDER: PRJNA918633 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22987321.fastq.gz	Fastqsanger.gz
	SRR22987322.fastq.gz	Fastqsanger.gz
	SRR22987323.fastq.gz	Fastqsanger.gz
	SRR22987324.fastq.gz	Fastqsanger.gz
	SRR22987325.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 87

Similar Datasets

Acquired immunotherapy resistance in PDA

Project description:Acquired immunotherapy resistance in PDA

| PRJNA918626 | ENA

Acquired immunotherapy resistance in PDA (ATAC-seq)

Project description:Acquired immunotherapy resistance in PDA (ATAC-seq)

| PRJNA918632 | ENA

Clinical and molecular features of acquired resistance to immunotherapy [RNA-seq]

Project description:Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFNγ response genes. Upregulation of IFNγ response genes is associated with putative routes of resistance characterized by signatures of persistent IFN signaling, immune dysfunction, and mutations in antigen presentation genes which can be recapitulated in multiple murine models of acquired resistance to PD-(L)1 blockade after in vitro IFNγ treatment. Acquired resistance to PD-(L)1 blockade in NSCLC is associated with an ongoing, but altered IFN response. The persistently inflamed, rather than excluded or deserted, tumor microenvironment of acquired resistance informs therapeutic strategies to effectively reprogram and reverse acquired resistance.

2024-01-11 | GSE249000 | GEO

Clinical and molecular features of acquired resistance to immunotherapy [ATAC-seq]

2024-01-11 | GSE249001 | GEO

Acquired resistance to targeted therapy confers cross-resistance to immunotherapy

Project description:Acquired resistance to targeted therapy confers cross-resistance to immunotherapy

| PRJNA548090 | ENA

Clinical and molecular features of acquired resistance to immunotherapy [RNA-seq]

Project description:Clinical and molecular features of acquired resistance to immunotherapy [RNA-seq]

| PRJNA1046561 | ENA

Acquired immunotherapy resistance in PDA (RNA-seq)

Project description:36 samples were sequenced with duplicates or triplicates

2023-08-08 | GSE222224 | GEO

scRNAseq reveals mechanisms of Merkel cell carcinoma acquired immunotherapy resistance [1]

Project description:Serial blood draws from a single patient and serial tumor biopsies from the same patient with metastatic Merkel cell polyomavirus Merkel cell carcinoma, who was treated with cellular immunotherapy targeting MCPyV (autologous endogenous T cell therapy) followed by checkpoint inhibitors (anti-PD1 and anti-CTLA4). The patient had a 22 month clinical response followed by late/acquired resistance. We performed scRNAseq using the 10x genomics 3' Chromium expression assay to determine potential mechanisms contributing to immunotherapy response and late resistance

2018-09-01 | GSE117988 | GEO

Acquired immunotherapy resistance in PDA

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-08-08 | GSE222225 | GEO

Clinical and molecular features of acquired resistance to immunotherapy [ATAC-seq]

Project description:Clinical and molecular features of acquired resistance to immunotherapy [ATAC-seq]

| PRJNA1046562 | ENA